# A Study of CS3002 in Subjects With Advanced Solid Tumors

> **NCT04162301** · PHASE1 · TERMINATED · sponsor: **CStone Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** CS3002

## Key facts

- **NCT ID:** NCT04162301
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-30
- **Primary completion:** 2021-02-19
- **Final completion:** 2021-02-19
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study has been stopped for strategic and business reasons.
- **Last updated:** 2021-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162301, "A Study of CS3002 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04162301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*